Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

• Published in: Cancer cell international 2022-08, Vol.22 (1), p.246-15, Article 246
• Main Authors: Ali, Eunus S, Akter, Shamima, Ramproshad, Sarker, Mondal, Banani, Riaz, Thoufiqul Alam, Islam, Muhammad Torequl, Khan, Ishaq N, Docea, Anca Oana, Calina, Daniela, Sharifi-Rad, Javad, Cho, William C
• Format: Article
• Language: English
• Subjects: Apoptosis; Biological products; Cancer; Cancer therapies; Cell cycle; Cell division; Cell signaling; Drug dosages; Drug therapy; Epigenetics; Extracellular signal-regulated kinase; Growth factors; Intracellular signalling; Kinases; MAP kinase; MAPK (ERK); Marine organisms; Metabolism; Metabolites; Molecular mechanisms; Mutation; Natural bioactive compounds; Natural products; Phytochemicals; Protein kinase; Proteins; Ras oncogenes; Ras signaling; Review; Reviews; Signal transduction; Tumor cells; Tumor microenvironment; Tumors
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-022-02666-z

MAPK (mitogen-activated protein kinase) or ERK (extracellular-signal-regulated kinase) pathway is an important link in the transition from extracellular signals to intracellular responses. Because of genetic and epigenetic changes, signaling cascades are altered in a variety of diseases, including cancer. Extant studies on the homeostatic and pathologic behavior of MAPK signaling have been conducted; however, much remains to be explored in preclinical and clinical research in terms of regulation and action models. MAPK has implications for cancer therapy response, more specifically in response to experimental MAPK suppression, compensatory mechanisms are activated. The current study investigates MAPK as a very complex cell signaling pathway that plays roles in cancer treatment response, cellular normal conduit maintenance, and compensatory pathway activation. Most MAPK inhibitors, unfortunately, cause resistance by activating compensatory feedback loops in tumor cells and tumor microenvironment components. As a result, innovative combinatorial treatments for cancer management must be applied to limit the likelihood of alternate pathway initiation as a possibility for generating novel therapeutics based on incorporation in translational research. We summarize current knowledge about the implications of ERK (MAPK) in cancer, as well as bioactive products from plants, microbial organisms or marine organisms, as well as the correlation with their chemical structures, which modulate this pathway for the treatment of different types of cancer.